Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
Κατάταξη σε μετοχές #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Τιμή μετοχής
$910.55
Κεφαλαιοποίηση
$860.30B
Αλλαγή (1 ημέρα)
0.44%
Αλλαγή (1 έτος)
5.28%
Χώρα
US
Εμπόριο Eli Lilly (LLY)

Κατηγορία

Ιστορικό μερισματικής απόδοσης για Eli Lilly (LLY)
Η μερισματική απόδοση (TTM) της Eli Lilly (σύμβολο μετοχής: LLY) στις 2024-12-31 ήταν: 0.67%
Μέση μερισματική απόδοση τα τελευταία 5 χρόνια: 0.84%
Ιστορικό μερισματικής απόδοσης για Eli Lilly (LLY) από 2000 έως 2026
Μερισματική απόδοση στο τέλος κάθε έτους (TTM)
Έτος Μερισματική απόδοση Αλλαγή
2026 (TTM) 0.63% 12.50%
2025 0.56% -16.42%
2024 0.67% -14.10%
2023 0.78% -23.53%
2022 1.02% -12.82%
2021 1.17% -29.52%
2020 1.66% -13.09%
2019 1.91% -1.55%
2018 1.94% -21.46%
2017 2.47% -7.49%
2016 2.67% 17.11%
2015 2.28% -16.79%
2014 2.74% -26.34%
2013 3.72% -3.88%
2012 3.87% -17.83%
2011 4.71% -15.74%
2010 5.59% 1.82%
2009 5.49% 17.56%
2008 4.67% 46.86%
2007 3.18% 3.58%
2006 3.07% 14.13%
2005 2.69% 7.60%
2004 2.50% 30.89%
2003 1.91% -2.05%
2002 1.95% 36.36%
2001 1.43% 27.68%
2000 1.12% 0.00%
Μερισματικές αποδόσεις (TTM) για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Μερισματική απόδοση Χώρα
1.64%
GB
2.15%
US
3.03%
US
3.05%
CH
2.84%
US